Viking Therapeutics, Inc. (VKTX) Reaches $4.06 After 9.00% Down Move; Renewable Energy Group, Inc. (REGI) Had 2 Bullish Analysts

December 30, 2017 - By Richard Conner

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) is a huge mover today! The stock decreased 3.56% or $0.15 during the last trading session, reaching $4.06. About 479,722 shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 5.04% since December 30, 2016 and is uptrending. It has underperformed by 11.66% the S&P500.The move comes after 9 months negative chart setup for the $142.35 million company. It was reported on Dec, 30 by Barchart.com. We have $3.69 PT which if reached, will make NASDAQ:VKTX worth $12.81M less.

Among 4 analysts covering Renewable Energy (NASDAQ:REGI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Renewable Energy had 19 analyst reports since August 5, 2015 according to SRatingsIntel. Piper Jaffray maintained Renewable Energy Group, Inc. (NASDAQ:REGI) rating on Wednesday, August 23. Piper Jaffray has “Hold” rating and $13.0 target. The stock has “Buy” rating by Canaccord Genuity on Thursday, June 8. The firm has “Neutral” rating by Piper Jaffray given on Thursday, November 3. The stock of Renewable Energy Group, Inc. (NASDAQ:REGI) earned “Hold” rating by Piper Jaffray on Friday, November 3. The rating was maintained by Canaccord Genuity with “Buy” on Sunday, November 5. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, July 27 report. Roth Capital maintained the shares of REGI in report on Thursday, September 28 with “Buy” rating. The stock has “Hold” rating by Zacks on Friday, August 7. The firm has “Hold” rating by Canaccord Genuity given on Wednesday, August 5. Canaccord Genuity maintained Renewable Energy Group, Inc. (NASDAQ:REGI) on Wednesday, September 27 with “Buy” rating. See Renewable Energy Group, Inc. (NASDAQ:REGI) latest ratings:

05/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0 Maintain
03/11/2017 Broker: Roth Capital Rating: Buy New Target: $17.0 Maintain
03/11/2017 Broker: Piper Jaffray Rating: Hold New Target: $13.0 Maintain
24/10/2017 Broker: Roth Capital Rating: Buy New Target: $17.0 Maintain
28/09/2017 Broker: Roth Capital Rating: Buy New Target: $17.0 Maintain
29/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $13.0 Maintain
27/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0 Maintain
23/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $13.0 Maintain
23/08/2017 Broker: Roth Capital Rating: Buy New Target: $17.0 Maintain
27/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $16.0000 Maintain

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $142.35 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on March, 20. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.22 actual earnings per share reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -13.64% EPS growth.

Among 4 analysts covering Viking Therapeutics (NASDAQ:VKTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics has $10 highest and $5.0 lowest target. $6.88’s average target is 69.46% above currents $4.06 stock price. Viking Therapeutics had 11 analyst reports since April 7, 2016 according to SRatingsIntel. The company was initiated on Thursday, April 7 by H.C. Wainwright. Maxim Group maintained Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday, July 12 with “Buy” rating. H.C. Wainwright reinitiated the stock with “Buy” rating in Friday, November 10 report. The firm has “Buy” rating by Maxim Group given on Tuesday, May 24. The stock has “Buy” rating by Maxim Group on Thursday, August 10. Maxim Group maintained the stock with “Buy” rating in Tuesday, June 6 report. Roth Capital initiated it with “Buy” rating and $5.0 target in Tuesday, November 21 report. The stock has “Buy” rating by Roth Capital on Wednesday, November 29. H.C. Wainwright maintained it with “Buy” rating and $700 target in Thursday, August 10 report. The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) has “Buy” rating given on Thursday, August 11 by Laidlaw.

Investors sentiment increased to 1.39 in 2017 Q3. Its up 0.01, from 1.38 in 2017Q2. It improved, as 14 investors sold Renewable Energy Group, Inc. shares while 40 reduced holdings. 29 funds opened positions while 46 raised stakes. 38.53 million shares or 2.49% more from 37.60 million shares in 2017Q2 were reported. Dimensional Fund Advsrs Lp has 0.02% invested in Renewable Energy Group, Inc. (NASDAQ:REGI) for 3.27 million shares. Goldman Sachs Gp Incorporated holds 0% of its portfolio in Renewable Energy Group, Inc. (NASDAQ:REGI) for 98,987 shares. Swiss Bank invested 0% in Renewable Energy Group, Inc. (NASDAQ:REGI). 49,110 are held by Ny State Common Retirement Fund. Prudential Inc accumulated 385,129 shares or 0.01% of the stock. Jpmorgan Chase accumulated 1.30M shares. Citigroup Incorporated has invested 0% of its portfolio in Renewable Energy Group, Inc. (NASDAQ:REGI). Hotchkis Wiley Capital Mgmt Ltd Liability has 11,414 shares. Thomson Horstmann And Bryant invested in 381,566 shares or 0.64% of the stock. California-based First Quadrant Lp Ca has invested 0% in Renewable Energy Group, Inc. (NASDAQ:REGI). Ameriprise Finance Incorporated reported 0% in Renewable Energy Group, Inc. (NASDAQ:REGI). Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,358 shares. Nomura reported 247,360 shares. Menta Capital Ltd Liability holds 0.12% or 67,042 shares in its portfolio. Thrivent Fincl For Lutherans has 0% invested in Renewable Energy Group, Inc. (NASDAQ:REGI).

Renewable Energy Group, Inc. produces and sells biofuels and renewable chemicals in the United States. The company has market cap of $458.23 million. It operates through Biomass-Based Diesel, Services, Renewable Chemicals, and Corporate and Other divisions. It currently has negative earnings. The Biomass-Based Diesel segment acquires feedstock; manages, constructs, and operates biomass diesel production facilities; and markets, sells, and distributes biomass diesel and its co-products.